Motilal Oswal believes Molbio's successful diversification beyond TB, stronger international adoption and improving cash conversion could support a re-rating, while dependence on government orders and elevated working capital remain key risks.
Motilal Oswal believes Molbio's successful diversification beyond TB, stronger international adoption and improving cash conversion could support a re-rating, while dependence on government orders and elevated working capital remain key risks.
<iframe src="https://hindustansphere.com/embed/cluster/983b9fa4fc576e690a12b0d861bbabe82bf87ea2" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Molbio Diagnostics Shares In Focus As Motilal Oswal Initiates Coverage; Check Target Price"></iframe>
